Medpace Holdings, Inc. (MEDP) EPS Diluted: 15.28
Is Medpace Holdings, Inc.’s EPS diluted high or low?
Medpace Holdings, Inc.'s EPS diluted of 15.28 is 74% above its 5-year average of 8.79, near the high end of its 5-year range (3.84–15.28).
9.49% above its 12-month average of 13.96.
MEDP EPS Diluted Chart
MEDP Average EPS Diluted Chart
MEDP Current vs Average EPS Diluted Chart
MEDP EPS Diluted Metrics
EPS DILUTED
15.28
EPS DILUTED AVG TTM
13.96
EPS DILUTED AVG 3Y
11.02
EPS DILUTED AVG 5Y
8.79
EPS DILUTED AVG 10Y
5.31
EPS DILUTED AVG 15Y
N/A
EPS DILUTED AVG 20Y
N/A
CURRENT VS TTM AVG
+9.49%
CURRENT VS 3Y AVG
+38.69%
CURRENT VS 5Y AVG
+73.90%
CURRENT VS 10Y AVG
+187.66%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Medpace Holdings, Inc. EPS Diluted Formula & Definition
EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. EPS Diluted FAQ
- What is the EPS diluted for Medpace Holdings, Inc. (MEDP)?
- The EPS diluted for MEDP stock is 15.28.
- Is Medpace Holdings, Inc.'s EPS diluted high or low?
- Medpace Holdings, Inc.'s EPS diluted of 15.28 is 74% above its 5-year average of 8.79, near the high end of its 5-year range (3.84–15.28).
- What is the TTM average EPS diluted for Medpace Holdings, Inc. (MEDP)?
- The TTM average EPS diluted for MEDP stock is 13.96.
- What is the 3Y average EPS diluted for Medpace Holdings, Inc. (MEDP)?
- The 3Y average EPS diluted for MEDP stock is 11.02.
- What is the 5Y average EPS diluted for Medpace Holdings, Inc. (MEDP)?
- The 5Y average EPS diluted for MEDP stock is 8.79.
- What is the 10Y average EPS diluted for Medpace Holdings, Inc. (MEDP)?
- The 10Y average EPS diluted for MEDP stock is 5.31.
Medpace Holdings, Inc. EPS Diluted History
| DATE | EPS DILUTED |
|---|---|
| 2025-12-31 | 15.28 |
| 2024-12-31 | 12.63 |
| 2023-12-31 | 8.88 |
| 2022-12-31 | 7.28 |
| 2021-12-31 | 4.81 |
| 2020-12-31 | 3.84 |
| 2019-12-31 | 2.67 |
| 2018-12-31 | 1.97 |
| 2017-12-31 | 0.98 |
| 2016-12-31 | 0.37 |
| 2015-12-31 | -0.28 |
| 2014-12-31 | -0.53 |
| 2013-12-31 | 1.28 |
Related Metrics
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle